Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bugan Lizhi Tang is a Traditional Chinese Medicine (TCM) herbal decoction developed by the Ankang Traditional Chinese Medicine Hospital Affiliated to Shaanxi University of Traditional Chinese Medicine. It is primarily indicated for the treatment of fatty liver disease and severe hypertriglyceridemia (SHTG). The formula is designed to tonify the liver and regulate lipid metabolism. In clinical research, it is often evaluated in combination with blood purification techniques like the Dual Plasma Exchange System (DFPP) to stabilize blood lipid oscillation and modulate lipid disorders. Research suggests that Bugan Lizhi Tang may exert its therapeutic effects by modulating the Hepatitis C virus core-binding protein 6 (HCBP6), which plays a role in lipid metabolism disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bugan Lizhi Tang.